A phase III randomized trial of gantenerumab in prodromal Alzheimer’s disease

BACKGROUND: Gantenerumab is a fully human monoclonal antibody that binds aggregated amyloid-β (Aβ) and removes Aβ plaques by Fc receptor-mediated phagocytosis. In the SCarlet RoAD trial, we assessed the efficacy and safety of gantenerumab in prodromal Alzheimer’s disease (AD). METHODS: In this rando...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Alzheimers Res Ther
Main Authors: Ostrowitzki, Susanne, Lasser, Robert A., Dorflinger, Ernest, Scheltens, Philip, Barkhof, Frederik, Nikolcheva, Tania, Ashford, Elizabeth, Retout, Sylvie, Hofmann, Carsten, Delmar, Paul, Klein, Gregory, Andjelkovic, Mirjana, Dubois, Bruno, Boada, Mercè, Blennow, Kaj, Santarelli, Luca, Fontoura, Paulo
Formato: Artigo
Idioma:Inglês
Publicado em: BioMed Central 2017
Assuntos:
Research
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5723032/
https://ncbi.nlm.nih.gov/pubmed/29221491
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13195-017-0318-y
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados